HITK Key Stats
- HI TECH PHARMACAL CO INC Files SEC form 8-K, Entry into a Material Definitive Ag... May 31
- HI TECH PHARMACAL CO INC Files SEC form 8-K, Entry into a Material Definitive Ag... May 28
- 7 Small-Cap Stocks With Heavy Insider Ownership May 24
- HITK Makes Bullish Cross Above Critical Moving Average May 22
- HITK January 2014 Options Begin Trading May 20
- Hi-Tech Pharmacal's Management Presents at Bank of America Merrill Lynch Health ... May 14
- Hi-Tech Pharmacal to Present at the Bank of America Merrill Lynch 2013 Health Ca... May 9
- Hi-Tech Pharma Announces ECR Pharma Re-Launched Zolpimist, DexPak, Divestiture o... Apr 30
- ECR Pharmaceuticals Announces Re-launch of Zolpimist® and DexPak®, Divestiture o... Apr 30
- Hi-Tech Pharmacal to Present at the Needham 12th Annual Healthcare Conference Business Wire Apr 29
HITK Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Hi-Tech Pharmacal is up 21.04% over the last year vs S&P 500 Total Return up 23.89%, Columbia Laboratories down 4.87%, and SciClone Pharmaceuticals down 33.29%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for HITK
Pro Report PDF for HITK
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download HITK Pro Report PDF
Pro Strategies Featuring HITK
Did Hi-Tech Pharmacal make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.